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The Third Way of Umbilical Cord Blood Banking
To the editor: 
Umbilical cord blood banks have traditionally been categorized into public and private banks. Critics usually regard the dichotomy as altruism versus self-interest. Some medical and bioethical bodies in the United States, the United Kingdom and Europe have issued statements to support public cord blood banking, and have critically questioned the benefit of private cord blood banking, particularly for low-risk families. However, maintaining a public bank requires enormous resources, and many public banks struggle financially. Hybrid models, which have been developed in the cord blood industry1, provide an alternative “third way”, and blur the boundary between public and private cord blood bank. Through the study of cord blood banks in Taiwan and China  (ERC 283219), I present two hybrid models which, I argue, facilitate cell exchange and allocate resource efficiently. I analyze these models in regard to cell exchange, quality and financial consideration. In addition, I discuss how these models facilitate the cooperation among cord blood bank and different parties.
The first model is the “public and private combination” model. In this model, an organization runs both a donation program and a family banking program separately. The bank has ownership of the donated cord blood, and the family banked cord blood belongs to the family. This model follows the standard of public banks to collect the donated cord blood.  Hence, the donated cells can be used for therapy, basic research, animal studies, clinical trials, system monitoring, and quality control, or be developed into a product. The banks could collaborate with scientists in research institutes, hospitals, and universities to provide the cells to different countries for transplantation, clinical trials and research. The collaboration brings mutual benefits because breakthroughs in research and clinical trials can increase the utilization of cord blood. The cord blood donation program in this model is supported by the income from the family banking program, which costs US$2,5003,500 to store one unit for 20 years, and from the release fee of the units for allogeneic transplants, which costs US$7,00030,000. This model has been adopted by California based company Stemcyte and the national licensed cord blood banks in China. 
The second model is the “donatable family banking (Cún juān hù lì)” model. The cord blood units are family banked, but they can be searched by the wider public. In this model, parents sign a commercial contract and pay a fee for the collection and storage of the cord blood sample. Different from the traditional family banking, units in this model are tested, and human leukocyte antigen (HLA) typed. The cord blood units are tested for the disease markers in the same way as in the public banks. HLA typing data are then published on international registries for search. If HLA is successfully matched, the parents can decide whether they want to keep the cord blood unit, sell it or donate it to the patient in need of an allogeneic transplant. This model overcomes the problem that family banked units cannot be searched nor circulated for the wider public, despite that fact that the likelihood that a family will ever use the unit is low. It is estimated that the inventory in private cord blood banks is double or triple that in the public banks.2 This model provides accessibility to the privately banked cord blood units for the public so that these units can be used more efficiently. In Asia, this model has been adopted by Bionet (BabyBanks) in Taiwan, Hong Kong Cord Blood Co. Ltd., and Shanghai Cord Blood Bank in China.
In these two models, ownership and accessibility of the units vary. In the “public and private combination” model, the company has ownership of the donated cord blood. The bank can provide the cells quickly for transplant because the cells are “on the shelf”. For example, Stemcyte has facilitated more than 1,700 cord blood transplants globally out of 29,000 donated cord blood units. In contrast, the ownership of the cells in the “donatable family banking” model belongs to the customer. A further informed consent is required from the owner before a unit can be released for transplantation. 
Apart from clinical use of stem cells, these cord blood banks collaborate with research institutes in two ways: one is to provide cells, and the other is to provide funds. Companies that operate the “public and private combination” model can provide donated stem cells to clinical trials, pre-clinical trials, animal studies, and basic research. Providing stem cells for research is not possible with the “donatable family banking” model because ownership resides with the customer. Nevertheless, these banks sometimes sponsor research and clinical trials, which helps advance the clinical application of stem cells. Compared to public banks that have restricted financial support, which constrains their research activity and collaboration, these banks are active in collaborating with research institutes in different ways. 
The donated cord blood units in the “public and private combination” model, and the units in the “donatable family banking” model, can both be found in the international registries. Nevertheless, since the intrinsic characteristics of these two models are different, the processing procedure and quality of the units vary. To collect the donated cord blood, the “public and private combination” model follows the donation procedure of a public bank regarding disease markers, volume requirement, and a six-month follow-up survey. In the “donatable family banking” model, the units are tested for disease markers, but it is unclear regarding this model’s requirement about volume or total nucleated cells (TNC), which are crucial for transplantation. 
As with public banks, both models charge a release fee when a unit is used for transplantation. Greater financial input is required for an organization that operates a “public and private combination” model because it does not charge collection and storage fees for the donated cord blood. However, this model attracts income from its family banking and the release fee of the donated units. Therefore, compared with the traditional public banks, this model lowers the risk of financial crisis. The financial burden to run the “donatable family banking” model is relatively light as it charges a collection and storage fee, and usually a release fee as well. In addition, although the price of “donatable family banking” is higher than traditional family banking for the extra services of HLA typing and uploading data to international registries, this model is still welcomed by parents who recognize that the likelihood of using cord blood within the family is very low, and they usually get monetary compensation when it is matched and used by a patient in need.
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